USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Feb 23, 2022 | Dec 2021 | $0.98 | - | $0.93 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Feb 23, 2022 | Dec 2021 | $84.86M | - | $76.27M |
Collegium Pharmaceutical, Inc's next earnings date is Wednesday, Feb 23, 2022 for the fiscal quarter ending Dec 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $0.98 | $0.92 | $1.09 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 4 | $3.68 | $3.65 | $3.75 |
| Dec 2022 | 6 | $4.35 | $4.00 | $4.96 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 1 | $0.99 | $0.99 | $0.42 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2021 | 0 / 1 | $3.68 | $3.68 | $1.56 |
| Dec 2022 | 0 / 1 | $4.38 | $4.38 | $2.24 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $84.86M | $82.06M | $87.60M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2021 | 6 | $340.42M | $337.60M | $342.50M |
| Dec 2022 | 6 | $375.68M | $363.07M | $398.01M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Nov 4, 2021 | Sep 2021 | $0.95 | - | - |
| Aug 5, 2021 | Jun 2021 | $0.95 | $0.41 | -57.04% |
| May 6, 2021 | Mar 2021 | $1.00 | $0.96 | -4.84% |
| Feb 25, 2021 | Dec 2020 | $0.97 | $0.93 | -4.07% |
| Nov 5, 2020 | Sep 2020 | $0.90 | $1.03 | 14.53% |
| Aug 5, 2020 | Jun 2020 | $0.86 | $0.95 | 10.21% |
| May 7, 2020 | Mar 2020 | $0.66 | $0.89 | 34.71% |
| Feb 27, 2020 | Dec 2019 | $0.10 | $0.16 | 57.12% |
| Nov 6, 2019 | Sep 2019 | $0.03 | $0.05 | 81.27% |
| Aug 7, 2019 | Jun 2019 | $-0.04 | $0.09 | 317.09% |
| May 8, 2019 | Mar 2019 | $-0.15 | $-0.05 | 64.31% |
| Feb 27, 2019 | Dec 2018 | $-0.12 | $-0.10 | 17.03% |
| Nov 8, 2018 | Sep 2018 | $-0.12 | $-0.25 | -104.73% |
| Aug 8, 2018 | Jun 2018 | $-0.33 | $-0.15 | 55.09% |
| May 9, 2018 | Mar 2018 | $-0.65 | $-0.57 | 12.04% |
| Mar 7, 2018 | Dec 2017 | $-0.55 | $-0.54 | 2.53% |
| Nov 8, 2017 | Sep 2017 | $-0.73 | $-0.45 | 38.19% |
| Aug 9, 2017 | Jun 2017 | $-0.81 | $-0.72 | 10.56% |
| May 10, 2017 | Mar 2017 | $-1.00 | $-0.79 | 20.80% |
| Mar 9, 2017 | Dec 2016 | $-1.08 | $-1.02 | 5.56% |
| Nov 10, 2016 | Sep 2016 | $-1.12 | $-1.13 | -1.35% |
| Aug 10, 2016 | Jun 2016 | $-0.82 | $-1.05 | -27.66% |
| May 10, 2016 | Mar 2016 | $-0.49 | $-0.68 | -38.07% |
| Mar 15, 2016 | Dec 2015 | $-0.44 | $-0.46 | -5.75% |
| Nov 12, 2015 | Sep 2015 | $-0.30 | $-0.46 | -53.33% |
| Aug 12, 2015 | Jun 2015 | $-0.29 | $-0.45 | -55.17% |
| May 12, 2015 | Mar 2015 | - | $-0.65 | - |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 25, 2021 | Dec 2020 | $0.85 | $3.79 | 346.22% |
| Feb 27, 2020 | Dec 2019 | $-0.73 | $0.26 | - |
| Feb 27, 2019 | Dec 2018 | $-1.82 | $-1.07 | - |
| Mar 7, 2018 | Dec 2017 | $-2.53 | $-2.50 | - |
| Mar 9, 2017 | Dec 2016 | - | $-3.88 | - |
| Mar 15, 2016 | Dec 2015 | - | $-2.02 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Nov 4, 2021 | Sep 2021 | $84.89M | - | - |
| Aug 5, 2021 | Jun 2021 | $84.77M | $82.94M | 0.98% |
| May 6, 2021 | Mar 2021 | $81.87M | $87.72M | 1.07% |
| Feb 25, 2021 | Dec 2020 | $76.27M | $76.27M | 1.00% |
| Nov 5, 2020 | Sep 2020 | $77.43M | $79.18M | 1.02% |
| Aug 5, 2020 | Jun 2020 | $74.40M | $78.06M | 1.05% |
| May 7, 2020 | Mar 2020 | $76.68M | $76.51M | 1.00% |
| Feb 27, 2020 | Dec 2019 | $73.33M | $74.20M | 1.01% |
| Nov 6, 2019 | Sep 2019 | $74.32M | $72.94M | 0.98% |
| Aug 7, 2019 | Jun 2019 | $75.67M | $75.04M | 0.99% |
| May 8, 2019 | Mar 2019 | $70.82M | $74.52M | 1.05% |
| Feb 27, 2019 | Dec 2018 | $73.86M | $73.43M | 0.99% |
| Nov 8, 2018 | Sep 2018 | $74.79M | $70.18M | 0.94% |
| Aug 8, 2018 | Jun 2018 | $72.20M | $73.06M | 1.01% |
| May 9, 2018 | Mar 2018 | $59.75M | $63.75M | 1.07% |
| Mar 7, 2018 | Dec 2017 | $9.88M | $10.79M | 1.09% |
| Nov 8, 2017 | Sep 2017 | $5.37M | $11.95M | 2.23% |
| Aug 9, 2017 | Jun 2017 | $3.64M | $3.56M | 0.98% |
| May 10, 2017 | Mar 2017 | - | $2.17M | - |
| Mar 9, 2017 | Dec 2016 | - | $1.30M | - |
| Nov 10, 2016 | Sep 2016 | - | $408.00K | - |
| Aug 10, 2016 | Jun 2016 | - | $0.00 | - |
| May 10, 2016 | Mar 2016 | - | $0.00 | - |
| Mar 15, 2016 | Dec 2015 | - | $0.00 | - |
| Nov 12, 2015 | Sep 2015 | - | $0.00 | - |
| Aug 12, 2015 | Jun 2015 | - | $0.00 | - |
| May 12, 2015 | Mar 2015 | - | $0.00 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 25, 2021 | Dec 2020 | $310.02M | $310.02M | 0.00% |
| Feb 27, 2020 | Dec 2019 | $295.82M | $296.70M | 0.30% |
| Feb 27, 2019 | Dec 2018 | $280.62M | $280.41M | -0.07% |
| Mar 7, 2018 | Dec 2017 | $27.64M | $28.48M | 3.02% |
| Mar 9, 2017 | Dec 2016 | - | $1.71M | - |
| Mar 15, 2016 | Dec 2015 | - | $0.00 | - |
COLL's next earnings date is Wednesday, Feb 23, 2022 for the fiscal quarter ending Dec 31, 2021.
According to analysts, the average EPS estimation for Collegium Pharmaceutical, Inc's next quarterly earnings is $0.98, with a low EPS estimation of $0.92, and a high estimation of $1.09.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 1 downward. The EPS 1 month trend is $0.99, the last 2 month trend is $0.99, and the 3 month trend is $0.42.
Based on analysts, the average revenue estimation is $84.86M, with a low revenue estimation of $82.06M, and a high estimation of $87.60M.
Collegium Pharmaceutical, Inc's previous earnings date was Nov 4, 2021 for its fiscal quarter ended Sep 30, 2021.
Collegium Pharmaceutical, Inc's previous annual earnings date was Feb 25, 2021 for its fiscal year ended Dec 31, 2020.
COLL's earnings per share (EPS) was $3.79, beating the consensus analysts forecast of $0.85 by 346.22% , and higher than the previous year's EPS (Dec 2019) by 1383.92%.
Revenues were $310.02M, better than the forecast of $310.02M by 0.00%, and up by 4.49% from previous year's revenue.
The company reported a net income of $26.75M.
Collegium Pharmaceutical, Inc reported a free cash flow of $-279.83M for its fiscal year, compared to $21.34M a year ago.
The company ended the fiscal year with $257.82M in total debt, an increase of 2020.92% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
